Related Experiment Video
Updated: Aug 16, 2026

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
Published on: May 12, 2020
Action of deferoxamine against Pneumocystis carinii
A B Clarkson1, D Turkel-Parrella, J H Williams
1Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York 10016, USA. clarka01@nyu.edu
Abstract:
We found earlier that deferoxamine (DFO), a drug used for treatment of iron overload, is active against a rat model of Pneumocystis carinii pneumonia (PCP). We had assumed a mode of action by deprivation of nutritional iron; however, data here show that DFO penetrates P. carinii, causing irreversible damage, thus indicating a different mode of action. Penetration was demonstrated by showing DFO uptake by high-pressure liquid chromatography analysis. By using calcein-AM as an indicator, exposure to DFO was shown to cause a reduction in P. carinii cytoplasmic free iron. Exposure to >or=100 microM DFO for >or=8 h in vitro caused growth to cease and cell numbers to decline over several days. This direct and irreversible damage to P. carinii led to the prediction that infrequent delivery of DFO to the lungs via an aerosol would be an effective treatment in the animal model of PCP. This prediction was confirmed by demonstrating that a once-a-week aerosol treatment of rats was 100% effective both as a prophylactic and as a curative treatment in a rat model of PCP.
Insights
Deferoxamine (DFO) directly damages Pneumocystis pneumonia (PCP) pathogens, not just by iron deprivation. Weekly aerosolized DFO proved 100% effective for preventing and treating PCP in a rat model.
Area of Science:
- Medical Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Deferoxamine (DFO), an iron overload drug, previously showed activity against Pneumocystis carinii pneumonia (PCP) in rats.
- The presumed mechanism of action was iron deprivation, but this study investigated a direct cellular effect.
Purpose of the Study:
- To elucidate the mode of action of deferoxamine (DFO) against Pneumocystis carinii.
- To evaluate the efficacy of aerosolized DFO for Pneumocystis pneumonia (PCP) treatment and prophylaxis.
Main Methods:
- Deferoxamine (DFO) uptake by P. carinii was measured using high-pressure liquid chromatography.
- Intracellular free iron levels were assessed using calcein-AM.
- In vitro growth inhibition and cell death assays were performed.
- Efficacy of weekly aerosolized DFO was tested in a rat model of PCP for prophylaxis and treatment.
Main Results:
- Deferoxamine (DFO) penetrates P. carinii and reduces intracellular free iron.
- Exposure to DFO leads to irreversible damage, cessation of growth, and cell number decline.
- Weekly aerosol administration of DFO was 100% effective in preventing and curing PCP in rats.
Conclusions:
- Deferoxamine (DFO) exerts a direct, irreversible cytotoxic effect on P. carinii.
- Infrequent aerosolized DFO delivery is a highly effective strategy for PCP treatment and prophylaxis in an animal model.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pharmaceutical Poisoning: Treatment Strategies
Rocky Mountain Spotted Fever
Cryptococcal Meningitis
Antiprotozoal Agents
